Smith & Nephew PLC (SNNUF) stock
Close on Oct 19, 2026Market cap –P/E 18.6Yield –
Smith & Nephew PLC grew revenue 6.1% to $6.16B over fiscal 2025. Operating income rose 20.9% to $794.00M, moving the operating margin from 11.3% to 12.9%.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 27, 2026
Valuation
- Market cap
- –
- P/E ratio
- 18.6
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $6.16B
- EPS, diluted
- $0.72
Trading
- Previous close
- $13.33
- Open
- $13.33
- Day's range
- $13.33 – $13.33
- Volume
- 0
- Beta (5 years)
- 0.64
- 52-week range
- $26.12 – $37.09
- RSI (14 days)
- 58.0
- Volatility (1 year)
- 28.7%
- Relative volume
- 1.11×
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | SNNUF | S&P 500 | Difference | SNNUF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.9% | +0.6% | −13.5 pts | ||
| 3 months | -4.4% | +3.4% | −7.8 pts | ||
| Year to date | -17.0% | +13.3% | −30.3 pts | ||
| 1 year | -23.2% | +16.6% | −39.8 pts | ||
| 3 years | +28.0% | +86.4% | −58.4 pts | +8.6% | +23.1% |
| 5 years | -11.2% | +81.9% | −93.0 pts | -2.3% | +12.7% |
| 10 years | +9.9% | +318.9% | −308.9 pts | +0.9% | +15.4% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Press releases
Releases Smith & Nephew filed with the SEC as exhibits to Form 8-K or 6-K
About Smith & Nephew
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Smith & Nephew plc is a global medical technology business providing specialized medical devices and clinical solutions. The company operates through core segments including Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its portfolio features hip and knee reconstruction implants, trauma systems, arthroscopic enabling technologies, and sports medicine joint repair tools. It also delivers advanced wound care, wound bioactives, and advanced wound devices to surgeons, hospitals, and healthcare professionals.
Company profile, executives and historySmith & Nephew stock: common questions
What is Smith & Nephew's stock price?
SNNUF closed at $13.33 on Oct 19, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $26.12 and $37.09.
What is SNNUF's P/E ratio?
SNNUF trades at 18.6 times earnings, based on diluted earnings per share of $0.72 over fiscal 2025.
How much revenue does Smith & Nephew make?
Smith & Nephew reported revenue of $6.16B for fiscal 2025, up 6.1% from a year earlier.
Does Smith & Nephew pay a dividend?
No. Smith & Nephew has not paid a cash dividend over the last twelve months.
How has SNNUF stock performed over the past year?
Including dividends, SNNUF returned -23.2% over the past year, against +16.6% for the S&P 500.
Who are Smith & Nephew's competitors?
Companies most similar to Smith & Nephew by business, industry and size include ENOV, ZBH, STE, ISRG, EW.